Sarfez Pharmaceuticals, Inc.
Small cardiovascular specialty pharmaceutical company focused on improving existing cardio-renal drugs and making them more accessible and affordable. Activities described include formulation platform development for oral and injectable dosage forms, clinical development and regulatory submission activities, partnerships with specialized contract organizations, and use of data analytics and virtual models to reduce development time and cost.
Industries
N/A
Products
Torsemide tablets (extended-duration formulation for edema)
Oral torsemide tablet formulation intended to treat edema associated with heart failure and renal disease; described tablet strengths include 20 mg, 40 mg, and 60 mg with a reported 6–8 hour diuretic duration.
Torsemide tablets (extended-duration formulation for edema)
Oral torsemide tablet formulation intended to treat edema associated with heart failure and renal disease; described tablet strengths include 20 mg, 40 mg, and 60 mg with a reported 6–8 hour diuretic duration.
Services
Sample distribution to licensed practitioners
Controlled provision of product samples to licensed practitioners via a sample request process for clinical use and evaluation.
Partnerships for outsourced development and manufacturing
Coordination and management of alliances with specialized contract development and manufacturing organizations to execute formulation development, manufacturing, and related activities.
Sample distribution to licensed practitioners
Controlled provision of product samples to licensed practitioners via a sample request process for clinical use and evaluation.
Partnerships for outsourced development and manufacturing
Coordination and management of alliances with specialized contract development and manufacturing organizations to execute formulation development, manufacturing, and related activities.
Expertise Areas
- Cardio-renal drug development
- Oral dosage formulation development
- Clinical trial design and execution
- Regulatory submissions and labeling
Key Technologies
- Matrix-based extended-release formulations
- Orally-disintegrating formulations
- Self-emulsifying drug delivery systems
- Oral solid, liquid and injectable dosage forms